HUM

Thinking of Buying Humana (HUM)? Here's What You Need to Know.

Shares of Health Care sector company Humana moved 1.7% today, and are now trading at a price of $500.35. The large-cap stock's daily volume was 1,193,664 compared to its average volume of 1,170,007. The S&P 500 index returned a -0.0% performance.

Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. The company is based in Louisville and has 67,100 full time employees. Its market capitalization is $61,598,588,928. Humana currently offers its equity investors a dividend that yields 0.7% per year.

18 analysts are following Humana and have set target prices ranging from $525.0 to $640.0 per share. On average, they have given the company a rating of buy. At today's prices, HUM is trading -14.51% away from its average analyst target price of $585.28 per share.

Over the last year, HUM shares have gone down by -8.0%, which represents a difference of -25.0% when compared to the S&P 500. The stock's 52 week high is $553.69 per share and its 52 week low is $423.29. With average free cash flows of $3.37 Billion that have been growing at an average rate of 21.4% over the last 6 years, Humana declining stock performance may not be reflective of the quality of its underlying business.

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k) YoY Growth (%)
2023 5,988,000 979,000 5,009,000 44.48
2022 4,587,000 1,120,000 3,467,000 266.49
2021 2,262,000 1,316,000 946,000 -79.76
2020 5,639,000 964,000 4,675,000 2.79
2019 5,284,000 736,000 4,548,000 191.35
2018 2,173,000 612,000 1,561,000
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS